Evidence map›Paper›PMID 34885095›Full record

ArticleCancers2021

Changes in the Proteome in the Development of Chronic Human Papillomavirus Infection-A Prospective Study in HIV Positive and HIV Negative Rwandan Women.

Emile Bienvenu, Marie Francoise Mukanyangezi, Stephen Rulisa, Anna Martner, Bengt Hasséus, Egor Vorontsov, Gunnar Tobin, Daniel Giglio

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Emile BienvenuCollege of Medicine and Health Sciences, University of Rwanda, KK 737 St, Gikondo, Kigali, Rwanda.
Marie Francoise MukanyangeziCollege of Medicine and Health Sciences, University of Rwanda, KK 737 St, Gikondo, Kigali, Rwanda.
Stephen RulisaCollege of Medicine and Health Sciences, University of Rwanda, University Teaching Hospital of Kigali (UTHK), KN 4 Ave, Kigali, Rwanda.
Anna MartnerTIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 41390 Gothenburg, Sweden.ORCID 0000-0002-6598-5221
Bengt HasséusDepartment of Oral Medicine and Pathology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
Egor VorontsovProteomics Core Facility, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
Gunnar TobinDepartment of Pharmacology, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
Daniel GiglioDepartment of Pharmacology, Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.ORCID 0000-0002-1349-9336
University of Gothenburg · SEUniversity of Kigali · RWSahlgrenska University Hospital · SEUniversity of Rwanda · RW

Funding

Stiftelsen Serena Ehrenströms Fond för Kräftsjukdomars Bekämpande och Stiftelsen Torsten och Sara Janssons Fondthe Assar Gabrielsson Foundation FB19-59the Gösta Milton Donation Foundationthe Swedish International Development Cooperation Agency (Sida)the Wilhelm and Martina Lundgren Foundation 2019-2833
6 · The paper itself

Abstract

backgroundEffects on the proteome when a high risk (HR)-HPV infection occurs, when it is cleared and when it becomes chronic were investigated. Moreover, biomarker panels that could identify cervical risk lesions were assessed.

methodsCytology, HPV screening and proteomics were performed on cervical samples from Rwandan HIV+ and HIV- women at baseline, at 9 months, at 18 months and at 24 months. Biological pathways were identified using the String database.

resultsThe most significantly affected pathway when an incident HR-HPV infection occurred was neutrophil degranulation, and vesicle-mediated transport was the most significantly affected pathway when an HR-HPV infection was cleared; protein insertion into membrane in chronic HR-HPV lesions and in lesions where HR-HPVs were cleared were compared; and cellular catabolic process in high-grade lesions was compared to that in negative lesions. A four-biomarker panel (EIF1; BLOC1S5; LIMCH1; SGTA) was identified, which was able to distinguish chronic HR-HPV lesions from cleared HR-HPV/negative lesions (sensitivity 100% and specificity 91%). Another four-biomarker panel (ERH; IGKV2-30; TMEM97; DNAJA4) was identified, which was able to distinguish high-grade lesions from low-grade/negative lesions (sensitivity 100% and specificity 81%).

conclusionsWe have identified the biological pathways triggered in HR-HPV infection, when HR-HPV becomes chronic and when cervical risk lesions develop. Moreover, we have identified potential biomarkers that may help to identify women with cervical risk lesions.

Indexed as

cervical cancerHIVHPVintraepithelial lesionproteomicsRwanda

Identifiers

PMID34885095
PMCPMC8656715
OpenAlexW3214794224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.